-
1.发明授权Process for producing hydrophobic polypeptides and proteins, and fusion proteins for use in producing same 失效用于制备疏水性多肽和蛋白质的方法，以及用于生产疏水性多肽和蛋白质的融合蛋白质
公开(公告)号：US5750374A
公开(公告)日：1998-05-12
申请号：US268348
申请日：1994-06-29
IPC分类号： C12N15/09 , C07K1/20 , C07K14/16 , C07K14/47 , C07K19/00 , C12N1/21 , C12N15/62 , C12P21/02 , C12R1/19 , C07K1/00 , C12P21/00 , C10P21/06
CPC分类号： C12P21/02 , C07K14/005 , C07K14/4711 , C12N15/62 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C12N2740/16122
摘要： Methods are disclosed for the production and purification of hydrophobic fusion proteins production and purification of said hydrophobic polypeptides, proteins or peptides. Homogeneous monomeric .beta.-amyloid peptide and tests for screening amyloid toxicity-inhibiting drugs using this monomeric .beta.-amyloid peptide relate to these fusion proteins.
摘要翻译： 公开了用于生产和纯化所述疏水性多肽，蛋白质或肽的疏水性融合蛋白产生和纯化的方法。 均匀单体β-淀粉样蛋白肽和使用该单体β-淀粉样肽筛选淀粉样蛋白毒性抑制药物的试验涉及这些融合蛋白。
-
公开(公告)号：US5284933A
公开(公告)日：1994-02-08
申请号：US158962
申请日：1988-02-22
IPC分类号： C12N15/09 , A61K38/00 , C07K1/22 , C07K14/00 , C07K14/52 , C07K14/555 , C07K14/57 , C07K19/00 , C12N1/20 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12R1/19 , C07K13/00
CPC分类号： C07K14/57 , C12N15/62 , C12N15/70 , A61K38/00 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/75
摘要： Fusion proteins and a process for their purification by means of metal chelate affinity chromatography on NTA resins are provided by this invention.
摘要翻译： 本发明提供融合蛋白及其通过NTA树脂上金属螯合亲和层析纯化的方法。
-
公开(公告)号：US5310663A
公开(公告)日：1994-05-10
申请号：US80043
申请日：1993-06-18
IPC分类号： C12N15/09 , A61K38/00 , C07K1/22 , C07K14/00 , C07K14/52 , C07K14/555 , C07K14/57 , C07K19/00 , C12N1/20 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12R1/19 , C12N15/00
CPC分类号： C07K14/57 , C12N15/62 , C12N15/70 , A61K38/00 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/75
摘要： Fusion proteins and a process for their purification by means of metal chelate affinity chromatography on NTA resins are provided by this invention.
-
公开(公告)号：US5597899A
公开(公告)日：1997-01-28
申请号：US217529
申请日：1994-03-24
IPC分类号： G01N33/566 , A61K38/00 , A61P35/00 , C07H21/02 , C07H21/04 , C07K14/52 , C07K14/525 , C07K14/705 , C07K14/715 , C12N1/21 , C12N15/00 , C12N15/09 , C12N15/19 , C12N15/28 , C12P21/02 , C12R1/19 , C12R1/91 , C12P21/06
CPC分类号： C07K14/525 , A61K38/00
摘要： Human TNF muteins having higher binding affinity for human p75-TNF receptor than for human p55-TNF receptor include muteins having at least one different amino acid relative to wild-type human TNF at a position corresponding to position 33, 65, 67, 75, 87, 143, 145 or 147 of the wild-type amino acid sequence.
摘要翻译： 对人p75-TNF受体具有比人p55-TNF受体更高的结合亲和力的人TNF突变蛋白包括相对于野生型人类TNF的至少一种不同氨基酸的突变蛋白，该位置对应于位置33,65,67,75， 87,143,145或147个野生型氨基酸序列。
-
公开(公告)号：US5486463A
公开(公告)日：1996-01-23
申请号：US41648
申请日：1993-04-01
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07K14/00 , C07K14/52 , C07K14/525 , C07K14/705 , C07K16/00 , C07K19/00 , C12N1/21 , C12N15/28 , C12P21/02 , C12R1/19 , C12P21/06 , C07H17/00 , C12N1/20
CPC分类号： C07K14/525 , A61K38/00
摘要： The present invention is directed to a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 having a threonine instead of a serine residue, a DNA sequence coding for such a mutein, a vector comprising such a DNA sequence, and a host cell transformed by such a vector.
摘要翻译： 本发明涉及对人p55-肿瘤坏死因子受体具有选择性结合亲和力的人类肿瘤坏死因子突变蛋白或其药学上可接受的盐，其特征在于至少改变人肿瘤坏死因子的氨基酸序列 在具有苏氨酸而不是丝氨酸残基的位置86，编码这种突变蛋白的DNA序列，包含这样的DNA序列的载体和由这种载体转化的宿主细胞。
-
-
-
-
搜索结果
5 条记录 (耗时 0.021 秒)
